Review

PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics

Alia Ghoneum 1 and Neveen Said 2,*

1 Departments of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
2 Departments of Cancer Biology, Pathology, and Urology, Wake Forest University School of Medicine, Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC 27157, USA

* Correspondence: nsaid@wakehealth.edu; Tel.: +01-336-718-9980

Received: 13 May 2019; Accepted: 30 June 2019; Published: 5 July 2019

Abstract: Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.

Keywords: PI3K-AKT-mTOR; NFκB; ovarian cancer; therapy

1. Introduction

Ovarian cancer (OvCa) is the fifth most common type of cancer and the primary cause of gynecological cancer death in the United States [1]. At least 70% of patients are diagnosed at advanced stages with poor survival rates [2]. Despite aggressive debulking surgeries and adjuvant or neoadjuvant chemotherapy, recurrence is encountered in 70–80% of patients with poor prognosis and high mortality. In addition, there are limited second line treatment options for resistant or recurrent disease [2–4]. Therefore, there is an unmet need to understand the most frequently altered pathways that promote disease progression, recurrence, and chemoresistance.

The Cancer Genome Atlas (TCGA) data revealed the hyperactivation of phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway in nearly 60% of patients with OvCa [1]. This pathway plays significant multifaceted roles in cancer cell growth, survival, metabolic programing, autophagy, transcription regulation, and angiogenesis [5–7]. Patients with high-grade serous cancer (HGSC) have several activating mutations with increased DNA copy numbers of p110α (PIK3CA) and p110β (PIK3CB) subunits of PI3K [6,8,9]. Other subunits with mutations in OvCa include: PI3K p85 (PIK3R1) [10,11], AKT1 [12], AKT2 [13], PTEN [14], INPP4B [15], and MTOR [16]. Moreover, the mutation profile of serous ovarian cystadenocarcinoma, generated from cBioPortal for Cancer Genomics (http://www.cbioportal.org/), indicates that several key players in the PI3K/AKT/mTOR/NFκB pathway are hyperactivated (Figure 1).
Phosphoinositide 3 kinase (PI3K) defines a class of lipid kinases that have the ability to phosphorylate the inositol ring 3'-OH group in inositol phospholipids and hence produce phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [17]. The importance of PI3K in signaling is tied to its highly regulated structure. PI3K comprises a family of enzymes divided into: Class I PI3K, which includes catalytic and regulatory subunits. Class IA PI3K includes three isomers (α, β, δ), all of which are activated through receptor tyrosine kinases (RTKs). Class IB includes the group (γ), which is activated via G protein coupled receptors (GPCR) [6,18]. The functions of this family of enzymes are as diverse as their structural derivatives. P110α is a driver of angiogenesis, while p110β, δ, and γ contribute to inflammatory responses. Moreover, p110δ and mTOR play a role in B cell survival during adaptive immunity [18]. Due to its ability to affect several downstream effectors, PI3K Class IA is composed of a regulatory subunit p85 along with the catalytic PI3K 110α subunit [19]. Class II PI3K is divided into three subtypes—PI3KC2α, PI3KC2β, and PI3KC2γ—all of which are catalytic subunits. While both PI3KC2α and PI3KC2β have an N-terminal with a clathrin binding region, PI3KC2α inhibits kinase activity and is implicated in clathrin-mediated endocytosis [20]. The N-terminal of PI3KC2β binds to the scaffold protein intersectin, which is involved in PtdIns(3)P synthesis [21]. Class III PI3K involves two subunits: vacuolar protein sorting 34 (Vps34), the catalytic subunit, and vacuolar protein sorting 15 (Vps15), the regulatory subunit. Vps15 works with Rab5 guanosine triphosphatase (GTPase) to coordinate the activity of Vps34 in endosomal maturation [22].

2.1. Interactions of PI3K with Upstream Regulators

Class IA and IB PI3K are activated when an extracellular growth factor or agonist has bound to their cognate receptor tyrosine kinases (RTKs) or to the G-protein coupled receptor (GPCR), respectively [6]. This causes phosphorylation and activation of the regulatory p85 subunit of PI3K followed by Ras activating the catalytic p110α subunit. The activated PI3K heterodimer (PI3K-110α and...
p85) leads to the conversion of phosphatidylinositol 4,5 bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [7]. PI3K is also involved in the extracellular matrix (ECM)-integrin-focal adhesion kinase (FAK) and/or integrin-like kinase (ILK) signaling pathway, which is integral for several cellular functions including cellular adhesion, cell cycle progression, cell migration, and invasion [23]. Activated integrins stimulate FAK, a cytoplasmic tyrosine kinase, which in turn activates PI3K [23]; in contrast, ILK is downstream of PI3K and uses the PIP3 generated to activate downstream targets such as AKT and glycogen synthase kinase 3 beta (GSK3β) [24] (Figure 2).

![Figure 2. Schematic illustration of the PI3K/AKT/mTOR/NFκB Pathway. Dashed arrows indicate indirect activation of nuclear factor-κ light chain enhancer of activated B cells (NFκB) by PI3K, AKT and mTOR.](image)

### 2.1.2. Interactions of PI3K with Downstream Effectors

PI3K triggers the activation of a wide range of downstream effectors via a pleckstrin homology (PH) domain [25]. Protein kinase B (PKB), also known as AKT, is the main effector of PI3K, and serves as a pivotal serine/threonine kinase with multiple downstream targets. Other effectors include kinases, such as Bruton’s tyrosine kinase (BTK), which is important for B-lymphocyte development and differentiation [26]. Effectors also include adaptors, such as GRB-associated binding protein (GAB1/2), tandem PH domain protein 1 (TAPP1), and dual adaptor for phosphotyrosine/3 phosphotyrosine (DAPP), all of which are important for downstream signaling responsible for survival, proliferation, and metastasis. Specific GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) convert guanosine diphosphate (GDP) to GTP which are critical in a cornucopia of cellular processes including cell cycle progression, survival, actin polymerization, cellular polarization, metastasis, and nuclear transport [27–29]. PI3K directly activates downstream AKT by docking it to the cellular membrane, and indirectly activates AKT via mammalian target of rapamycin complex 2 (mTORC2) and phosphoinositide-dependent kinase-1 (PDK1), which in turn phosphorylate AKT at the serine 473 and threonine 308 sites, respectively [5,6,30].
2.1.3. The Importance of PI3K 110α in OvCa

In HGSC, PI3K p110α is the most hyper-activated subunit within the PI3K pathway, being altered in nearly 70% of cases [5,31]. Studies have found that mutations in the gene encoding PI3K p110α, PIK3CA, are found in nearly 33% of clear-cell carcinoma cases, with the region of 3q26 having increased copy numbers in about 7 out of 9 established OvCa lines [32,33]. PIK3CA-activating mutations occur in 20% of endometrioid and clear-cell carcinomas [34]. TCGA data revealed activating mutations and amplifications of PIK3CA in 18–28% of cases of serous cystadenocarcinoma, with enrichment of the signature of activated PI3K in a majority of cases irrespective of the subtype [31]. In addition, multivariate survival analysis revealed that PI3K protein expression scores were associated with poor survival in advanced HGSC; in contrast, in univariate analysis, no significant correlation between PI3K protein expression and survival was found [35]. Consistently, data from the Cancer Cell Line Encyclopedia (CCLE) and Domcke et al. [36] revealed activating mutations and amplifications in PIK3CA in serous, clear-cell, mucinous, and mixed subtype OvCa cell lines, including cell lines that have been extensively used in preclinical models of OvCa (Table 1). The increased activation of PI3K in OvCa and its role as a hub for several cancer-promoting pathways, explain its many implications in cancer progression including oncogenic transformation, cell proliferation, adhesion, and apoptosis, as well as multiple metabolic pathways [5,7,37–39]. PI3K is activated by the over-expressed/hyper-activated receptor tyrosine kinases, such as epidermal growth factor receptors (EGFRs), vascular endothelial growth factor receptors (VEGFRs), and platelet-derived growth factor receptors (PDGFRs) [40], as well as receptors for lysophosphatidic acid (LPA) [41], bioactive lipids, cytokines/chemokines [42], prostaglandin E2 (PGE2) [43], endothelin [44], and angiotensinogen [45–48], inducing a plethora of pro-survival, pro-invasive, and pro-inflammatory mediators that further promote OvCa proliferation and invasiveness [41]. Thus, activation of PI3K was shown to be inhibited by RTK and FAK inhibitors, as well as cytokine/chemokine/receptors inhibitors leading to inhibition of OvCa cells migration and invasion through inhibiting downstream PI3K-AKT signaling [49].
Table 1. Summary of mutations in the PI3K-AKT pathway in 13 OvCa cell lines collected from Cancer Cell Line Encyclopedia (CCLE), https://oncokb.org, and [36].

| Cell Line | Annotation                                                   | PI3K                                      | PTEN                         | AKT               |
|-----------|-------------------------------------------------------------|-------------------------------------------|-------------------------------|-------------------|
| A2780     | Unlikely HGSC/not-specified                                 | PIK3CA Missense p.E365K                  | Deletion                      | AKT3 Gain         |
| CAOV3     | Likely HGSC/adenocarcinoma                                  | PIK3CA amplification                     |                               | AKT1/2 Gain       |
| IGROV1    | Mixed subtype/hypermutated                                  | PIK3CA Missense/non-stop p.R38C & p.1069W |                               | p.Y155C Loss of function |
| MCAS      | Mucinous cystadenocarcinoma                                 | PIK3CA Missense p.H1047R                 |                               | Gain              |
| OVMIU     | Not-specified                                              | PIK3CA Missense p.H1047R                 |                               |                   |
| OVSE      | Clear-cell                                                 | PIK3CA Missense p.E545V                  |                               |                   |
| OC314     | Serous                                                     | PIK3CA Missense p.R108H                  |                               | AKT2 Gain         |
| OC316     | Low-differentiated adenocarcinoma                           | PIK3CA Missense p.C420R                  | Heterozygous loss             | AKT1 Gain         |
| EFO27     | Mucinous                                                   | PIK3CA Missense p.H510N                  |                               |                   |
| COV318    | Serous/non-specified?                                       | PIK3CA Gain/amplification?               |                               | AKT1/2/3 Gain     |
| OVCA3     | Poorly differentiated papillary adenocarcinoma/possibly HGSC| PIK3CA AMP                               |                               | AKT2 amplification/Gain |
| SKOV3     | Moderately well-differentiated adenocarcinoma/mixed subtype | PIK3CA Missense p.H1047R                 | Heterozygous loss             |                   |
| TOV21G    | Clear-cell                                                 | PIK3CA Missense p.H1047Y                 |                               | Gain              |
| OAW42     | Non-specified                                              | PIK3CA Missense p.H1047Y                 |                               |                   |
| FUOV1     | Serous                                                     | PIK3CA Missense p.H1047L                 | Heterozygous loss             |                   |
2.1.4. Correlation of PI3K Mutations in OvCa with Standard of Care Therapy

The vast majority of HGSC patients will experience recurrence with platinum or taxane resistance [50]. Several preclinical studies using cell-based assays indicated that chemo-resistance, specifically to taxanes, is highly correlated with PI3K activation and hyperactivating mutations [51,52]. In OVCAR3, PIK3CA is amplified (six copies) and PIK3R1 contains a splice site on chromosome 5. In SKOV3, PIK3CA contains a missense mutation on chromosome 3. In CaOv3, PIK3CA is amplified with 6.7 copies, and in IGROV1, both PIK3CA and PIK3CB contain missense mutations on chromosome 3 (Table 1). Importantly, the PIK3CA mutation most commonly detected in human cancers include OvCa patients’ specimens and OvCa cell lines is the H1047R mutation [53]. Further analysis of several human OvCa cell lines revealed that PIK3CA mutations coexisted with KRAS and/or PTEN mutations indicating the requirement of a secondary defect in a co-regulator of PI3K activity for mutant PIK3CA to promote transformation. This was further supported by conditional activation of this mutation in the mouse ovary, showing that Pik3caH1047R alone was capable of inducing premalignant hyperplasia with no tumors of the ovarian surface epithelium. A concomitant Pik3caH1047R mutation plus PTEN deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and granulosa cell tumors. Both mutational events were required for early, robust Akt activation [53]. Pharmacological inhibition of PI3K/mTOR in these mice delayed tumor growth and prolonged survival. Several studies have shown that the rate of mutations in the PI3K pathway, especially in p-AKT and p-p70S6K, including missense mutations and amplifications, is correlated with higher rates of chemoresistance [52,54]. Chemo-sensitization could be achieved via downregulation of PI3K and/or its downstream effectors AKT and mTORC1 [55–57]. Consistently, in cell lines and 3D OvCa culture models, cisplatin resistance was overcome via upregulation of the tumor suppressor phosphatase and tensin homolog (PTEN) and downregulation of PI3K p110α, as well as the phosphorylated form of AKT (pAKT) [58–61]. Importantly, TCGA data analysis (http://kmplot.com/analysis) [62] revealed that the high expression of transcripts encoding PI3K subunits are correlated with poor patient survival (Figure 3). Moreover, there is a significant tendency of co-occurrence of PI3K/AKT/mTOR/NFκB mutations and alteration in OvCa (Table 2). While significant evidence exists that implicate mutations in PI3K/AKT/mTOR/NFκB in OvCa aggressiveness, it is important to note that the genomic architecture of OvCa is heterogeneous and multifaceted. PIK3CA mutations are considered driver mutations that provide transformative and positive advantages for cancer cells growing mainly in clear-cell, endometroid, and mucinous OvCa [63]. An integrated study of multi-omics data collected from the TCGA indicated that in HGSC, driver genes included well-known genes such as CCNE1 (cyclin E1), CDKN2A (p16), KRAS (Kirsten rat sarcoma), PTEN, and RB1 (retinoblastoma protein 1), as well as more obscure genes such as EVI2A (ectropic viral integration site 2A), C1orf114 (coiled-coil domain containing 181), and LCP2 (lymphocyte cytosolic protein 2) [64,65]. Thus, in HGSC, PTEN inactivation is considered an activating factor for PIK3CA.

Table 2. Summary of the tendencies of PI3K/AKT/mTOR/NFκB mutations to co-occur in OvCa (curated from http://www.cbioportal.org).

| A         | B         | Both | Log2 Odds Ratio | p-Value | q-Value |
|-----------|-----------|------|-----------------|---------|---------|
| PIK3CA    | PIK3CB    | 117  | 2.813           | <0.001  | <0.001  |
| PIK3CA    | AKT3      | 60   | 1.272           | <0.001  | <0.001  |
| PIK3CB    | MTOR      | 21   | 2.009           | <0.001  | <0.001  |
| PTEN      | AKT1      | 23   | 1.814           | <0.001  | <0.001  |
| AKT1      | IKBKB     | 23   | 1.659           | <0.001  | <0.001  |
| PIK3CA    | PTEN      | 75   | 0.918           | <0.001  | <0.001  |
| PIK3R1    | MTOR      | 14   | 2.132           | <0.001  | <0.001  |
| PIK3CA    | RELA      | 37   | 1.343           | <0.001  | <0.001  |
| PIK3CA    | MTOR      | 47   | 1.109           | <0.001  | <0.001  |
| AKT3      | MTOR      | 16   | 1.808           | <0.001  | <0.001  |
| AKT2      | AKT3      | 20   | 1.576           | <0.001  | <0.001  |
| PTEN      | NFKBIA    | 15   | 1.875           | <0.001  | <0.001  |
Table 2. Cont.

|   | A              | B              | Both | Log2 Odds Ratio | p-Value | q-Value |
|---|----------------|----------------|------|-----------------|---------|---------|
| PIK3R1 | IKBKB         | 19             |      | 1.607           | <0.001  | <0.001  |
| AKT1   | NFKB2         | 8              |      | 2.582           | <0.001  | <0.001  |
| PTEN   | MTOR          | 19             |      | 1.484           | <0.001  | 0.001   |
| AKT2   | IKBKB         | 26             |      | 1.247           | <0.001  | 0.001   |
| IKBKB  | NFKB1A        | 14             |      | 1.598           | <0.001  | 0.004   |
| PIK3CB | NFKB1         | 8              |      | 2.15            | 0.001   | 0.005   |
| PIK3R1 | AKT1          | 11             |      | 1.679           | 0.002   | 0.006   |
| PTEN   | NFKB2         | 9              |      | 1.929           | 0.002   | 0.006   |
| PIK3CB | NFKB2         | 8              |      | 2.034           | 0.002   | 0.007   |
| PIK3CA | AKT2          | 57             |      | 0.707           | 0.002   | 0.008   |
| AKT3   | NFKB2         | 7              |      | 2.08            | 0.003   | 0.009   |
| MTOR   | NFKB1         | 6              |      | 2.205           | 0.004   | 0.011   |
| PIK3CB | AKT1          | 14             |      | 1.248           | 0.005   | 0.016   |
| PIK3CB | NFKB1A        | 10             |      | 1.474           | 0.006   | 0.019   |
| AKT2   | NFKB1A        | 10             |      | 1.449           | 0.007   | 0.021   |
| PIK3CA | NFKB1A        | 27             |      | 0.897           | 0.008   | 0.023   |
| AKT3   | NFKB1         | 6              |      | 1.922           | 0.008   | 0.023   |
| PIK3CB | AKT2          | 17             |      | 0.982           | 0.012   | 0.03    |
| AKT2   | MTOR          | 13             |      | 1.12            | 0.013   | 0.031   |
| PIK3CA | IKBKB         | 68             |      | 0.501           | 0.013   | 0.031   |
| NFKB1  | NFKB1A        | 4              |      | 2.245           | 0.014   | 0.032   |
| RELA   | NFKB1A        | 6              |      | 1.728           | 0.014   | 0.032   |
| RELA   | IKBKB         | 12             |      | 1.106           | 0.018   | 0.04    |
| AKT1   | AKT3          | 11             |      | 1.129           | 0.02    | 0.043   |
| RELA   | NFKB1         | 4              |      | 2.051           | 0.021   | 0.045   |
| RELA   | NFKB2         | 4              |      | 1.945           | 0.026   | 0.054   |
| PIK3CA | NFKB2         | 16             |      | 0.96            | 0.027   | 0.054   |
| PIK3CB | PTEN          | 18             |      | 0.772           | 0.032   | 0.062   |
| AKT3   | RELA          | 8              |      | 1.176           | 0.036   | 0.068   |

Figure 3. Kaplan–Meier (KM) plots indicating the correlation of PI3K/AKT/mTOR/NFκB expression with patient survival. *p < 0.05. KM curves were generated via a KM plot using only JetSet best probe set with analysis restricted to: Serous and Stages 3 + 4.
3. Protein Kinase B PKB/AKT

3.1. Structural Overview

The AKT/PKB family encompasses a group of serine threonine kinases, which are cAMP- and cGMP-dependent [66]. The three AKT isoforms—AKT1 (PKBα), AKT2 (PKBβ), and AKT3 (PKBγ)—all contain a conserved N-terminal plekstrin homology (PH) domain, a central kinase domain, and a C-terminal regulatory domain that holds a hydrophobic region. The PH domain binds to the PIP3 at the inner side of the cell membrane and allows for the phosphorylation and activation of AKT [17,67]. The serine and threonine phosphorylation sites vary in each isoform, giving each its own unique role. AKT1 is involved in cellular growth, angiogenesis, and tumor cell invasiveness. AKT2 mediates glucose homeostasis and AKT3 aids in neuronal development and processing. AKT1 and AKT3 together are involved in embryonic development, while AKT1 and AKT2 act to regulate adipogenesis, as well as skin, bone, brain, and muscle development [68–74].

3.1.1. Upstream AKT Activation

AKT is the main kinase that integrates upstream signals from PI3K and mammalian target of rapamycin complex 2 (mTORC2) with downstream signals to mTORC1 (Figure 2). These signals play a pivotal role in the phosphorylation of downstream substrates and dictate several cellular activities including survival, proliferation, and migration [38,66,70]. AKT is activated via several mechanisms such as recruitment to the membrane by PIP3, phosphorylation at the threonine 308 site by PDK1, and phosphorylation at the serine 473 site by mTORC2. Activated phospho-AKT phosphorylates and activates mTORC1 at serine 248, either directly or indirectly, by inhibiting tuberous sclerosis complex 1 and 2 (TSC1/2) [67,75–77].

3.1.2. Downstream Effectors of AKT

AKT affects broad downstream targets that induce proliferation and cell cycle progression, apoptosis, and protein synthesis and cell growth [67]. The role of AKT in cell proliferation is mediated via the inhibition of several substrates. AKT phosphorylates GSK-3α at serine 21 and GSK-3β at serine 9, which inhibit GSK-3 kinase activity, thereby halting glycogen synthase, the key enzyme in glycogenesis, which is an important pathway for tumor cell metabolism [78,79]. In turn, GSK-3 phosphorylates several targets, including beta catenin, cyclin D1, and Myc, leading to their polyubiquitination and proteasomal degradation [67]. AKT inhibits Forkhead Box O4 (FOXO4), a transcription factor that induces cyclin D kinase (CDK) inhibitors, p21 (CIP1), and p27 (KIP1) [67]. Furthermore, AKT phosphorylates CDK inhibitors p21 and p27, hence mitigating their inhibitory effect on cyclins D and E, conferring AKT’s integral role in the regulation of cell cycle progression [66,67].

With regard to its anti-apoptotic effects, AKT inhibits several downstream signaling molecules, including caspase 9, while phosphorylating serine 136 of the Bcl2 associated death protein (BAD), leading to the dissociation of Bcl-2 on the mitochondrial membrane and inhibition of apoptosis [66,80]. Moreover, AKT phosphorylates the Forkhead family of transcription factors (FOXO), causing them to bind to 14-3-3 proteins, thus preventing the nuclear translocation of FOXO-1 and FOXO-3, as well as preventing apoptosis in cancer cells [81]. AKT also activates nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and cAMP responsive element binding protein (CREB), as well as anti-apoptotic genes such as X-linked inhibitor of apoptosis (XIAP), survivin, and inhibitor of nuclear transcription factor κB (IkB) kinase [9]. In addition, in vitro studies demonstrated that constitutively active AKT allows for activation and nuclear translocation of mouse double minute 2 homolog (MDM2), an E3 ubiquitin protein ligase that degrades p53, reducing cellular p53 levels, and thereby reduces p53 transcriptional activity [82,83]. Moreover, AKT promotes protein synthesis and cell growth by inhibiting TSC2, a tumor suppressor that is responsible for inhibiting cell growth in various cancer types, and 4E-binding protein 1 (4E-BP1), a regulator of mRNA translation and cellular proliferation [7,9,67,84,85].
3.1.3. Inhibition of AKT.

AKT is inhibited by tumor suppressors including PTEN and inositol polyphosphate 4-phosphatase type II (INPP4B). PTEN dephosphorylates PIP3 to produce PIP2, hence decreasing the downstream activation of phosphoinositide-dependent kinase-1 (PDK1) and phosphorylation of AKT [67,86]. It is important to note that the PTEN/PI3K/AKT pathway is not linear [87]. Transgenic mice with Pten deletion/mutation exhibited accelerated tumorigenesis and increased levels of activated AKT [88]. However, in Pten-deficient prostate cancer models, deletion of the p110β, but not p110α, subunit of PI3K was able to inhibit tumorigenesis and AKT activation [89], implying the direct effect of p110β-PI3K on AKT activation. These were also reported in patients with various neoplasms including OvCa, endometrial [90], esophageal cancers [91], and prostate cancers, as well as B-cell chronic lymphocytic and acute myeloid leukemia [92,93]. Another mechanism of inactivation of AKT is through INPP4B, which dephosphorylates and inactivates PI 3,4 bisphosphate (P13, 4P2), a direct activator of AKT, thereby obstructing AKT-induced downstream signaling. Loss of function mutations of INPP4B are highly prominent in OvCa [94] and have been correlated with increased ovarian and breast tumorigenicity in xenograft models and across patient samples [67,95–97].

3.1.4. AKT in OvCa

In OvCa, activated AKT causes growth deregulation and strong resistance to apoptotic stimuli, leading to uncontrolled tumor growth and cell invasion [7]. AKT is classified as an oncogene when there is a point mutation at the PH domain, and can be activated, independent of upstream PI3K signaling. Specifically, studies have indicated that AKT1 is mutated at E17K and Q79K sites, and AKT2 is amplified in about 40% of OvCa [7,98]. AKT overexpression in OvCa increases their susceptibility to platinum resistance [54]. Ectopic overexpression of AKT in OvCa cell lines increased their cisplatin resistance [99]. Cisplatin-resistant OvCa cell line A2780cis exhibited higher AKT expression levels than its cisplatin sensitive isotype [100]. Similarly, cell lines expressing higher levels of the activated AKT (phosphoAKT) were more resistant to paclitaxel [54,101]. Survival analysis of advanced stage HGSC (stages 3 + 4) in TCGA data using Kaplan–Meier (KM) plot (http://kmplot.com/analysis) [62] indicates that higher expression levels of AKT isoforms is associated with poor patient survival rates (Figure 3).

4. Mammalian Target of Rapamycin (mTOR)

4.1. Structural Overview

mTOR comprises two biochemically and functionally independent catalytic complexes, mTORC1 and mTORC2. The two complexes share two subunits, DEP domain containing mTOR-interacting protein (DEPTOR) and mammalian lethal with SEC18 protein 8 (mLst8) (Figure 2). Subunits unique to mTORC1 are Raptor and protein rich AKT substrate 40 (PRAS40), and those unique to mTORC2 are protein observed with Rictor-1 (Protor), mammalian stress-activated protein kinase interacting protein 1 (mSin1), and Rictor [102–105]. Higher expression levels of mTOR correlated with poor survival rates (Figure 3). Moreover, several studies have demonstrated that along with AKT, mTOR is highly hyperactivated and mutated in OvCa, warranting the use of mTOR inhibitors as targeted therapies after standard of care therapies, and in several clinical trials (Table 3) [76,77,106].
Table 3. Current clinical trials targeting the PI3K/AKT/mTOR/NFκB pathway in OvCa.

| Drug                          | Target                     | Clinical Trial | NCT Trial       |
|-------------------------------|----------------------------|----------------|-----------------|
| CUDC-907                      | PI3K/HDAC                 | Phase 1        | NCT02307240     |
| Copanlisib                    | PI3K                       | Phase 1b       | NCT03586661     |
| BKM120/BYL719                 | PI3K                       | Phase 1        | NCT01623349     |
| MK2206                        | AKT                        | Phase 2        | NCT01283035     |
| BKM120 + MEK162               | PI3K                       | Phase 1        | NCT01363232     |
| AZD5363                       | AKT                        | Phase 1        | NCT01226316     |
| GSK2141795                    | AKT                        | Phase 1        | NCT01256954     |
| Triciribine (PTX-200)         | AKT                        | Phase 1        | NCT01690468     |
| Miransertib (ARQ 092)         | AKT                        | Phase 1b       | NCT02476955     |
| Perifosine                    | PI3K/ AKT                  | Phase 1        | NCT00431054     |
| Sapanisertib                  | mTOR                       | Phase 2        | NCT02465060     |
| Everolimus                    | mTOR                       | Phase 2        | NCT01149434     |
| Nanoparticle albumin-bound rapamycin | mTOR                      | Phase 1        | NCT02646319     |
| Sirolimus                     | mTOR                       | Phase 1        | NCT02833506     |
| TAK228                        | PI3K/ AKT/mTOR             | Phase 2        | NCT03648489     |
| MLN0128                       | TORC 1/2                   | Phase 1        | NCT02142803     |
| Temsirolimus                  | mTOR                       | Phase 2        | NCT02093598     |
| AZD2014                       | mTOR                       | Phase 1b       | NCT02083875     |
| IMX-110                       | Stat3/NF-kb/poly-tyrosine kinase | Phase 1/2a  | NCT03382340     |

4.1.1. Upstream Activation of mTORC1

Both mTOR complexes are implicated in the induction of angiogenesis, proliferation, and cellular survival [6,103]. For example, during the M-phase of the cell cycle, the active form of mTOR, phospho-mTOR, is expressed at high levels in ovarian granulosa cells, suggesting its instrumental role in cellular checkpoint regulation [107]. mTORC1 plays an important and complex role in nutrient delivery and cellular energy, acting as a cellular energy sensor through AMP-activated protein kinase (AMPK) [102,108]. Once energy levels in the cell decline, AMPK is activated, leading to a downregulation of energy-consuming processes like protein synthesis, and in turn, initiates energy-generating processes such as fatty acid oxidation [108,109]. In addition to the involvement of mTOR with AMPK and cell cycle checkpoints, there is extensive crosstalk between AKT and mTORC1. There are two mechanisms by which AKT activates mTOR. AKT can directly phosphorylate and activate mTORC1, and can indirectly inhibit TSC1/2, activating Ras homolog enriched in brain (RHEB), a GTP-binding protein that activates mTORC1 [77,103]. Moreover, AMPK has been shown to inhibit mTORC1 via two mechanisms, by phosphorylating and activating TSC2, or by phosphorylating RAPTOR and disrupting the mTORC1 complex configuration. Several studies have suggested that PI3K class III member, VPS34, has a regulatory interaction with mTORC1. The inhibitory effect of AMPK on Raptor and the effect of VPS34 on mTORC1 lead to downstream autophagy in malignant cells [102,110–112].

4.1.2. Downstream Effectors of mTORC1

Phospho-mTOR activates two downstream targets: the 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase (S6K). Upon stimulation, 4E-BP1 dissociates from eukaryotic translation initiation factor 4E (eIF4E), leading to the subsequent formation of the eIF4F complex and translation initiation [113]. 4E-BP1 influences the metabolic components of the tumor microenvironment by regulating specific mRNA translational events [113–116]. Specifically, in aggressive cancers, 4E-BP1 functions as a hypoxia-inducible switch, allowing for translation of factors, such as VEGF, HIF1α, and Bcl2, and hence facilitating angiogenesis and anti-apoptotic cell growth [85,117]. Phosphorylated S6K is required for cell growth and G1 cell cycle progression [102,109]. The activated mTOR also causes selective translation of proteins involved in survival, including survivin, myeloid leukemia sequence 1 (Mcl1), and X-linked inhibitor of apoptosis (XIAP); angiogenic factors, such as vascular...
endothelial growth factor A (VEGF-A) and fibroblast growth factor 2 (FGF2); and DNA repair genes, such as breast cancer 1 (BRCA1), p53 binding protein 1 (53BP1), and H2A histone family member X (γH2AX) [37,75–77].

4.1.3. Upstream Regulators of mTORC2

While the upstream regulators of mTORC1 have been established over several studies, regulators for mTORC2 are less clearly defined. Several hypotheses have been proposed to explain mTORC2 regulation. Liu et al. [118] proposed a model whereby stress-activated protein kinase (SAPK)-interacting protein 1 (SIN1) binds and inactivates mTORC2 enabling PIP3 to free mTORC2 from SIN1, and thus, allowing for AKT phosphorylation. A second model proposes a positive feedback mechanism between AKT and mTORC2 whereby AKT phosphorylates SIN1, leading to activation of mTORC2 kinase. mTORC2 then phosphorylates AKT, catalyzing the full activation of AKT [119]. The third hypothesis implies that the TSC complex (TSC1/2) physically associates with and activates mTORC2 in a GTPase-independent manner [120,121]. These hypotheses all suggest that upstream molecules exert a highly complex regulation of mTORC2 signaling.

4.1.4. Downstream Effectors of mTORC2

The Rictor-mTOR complex forms a hydrophobic motif kinase that phosphorylates and activates AKT on the ser473 [122]. While both Rictor and Sin1 act in conjunction with mTOR, they can also act independently of the mTORC2 complex [102]. Rictor can independently activate ILK, myosin 1C (Myo1c), and cullin1 (CUL1); while Sin1 can activate c-Jun N-terminal kinase (JNK), Ras, and MAPK/ERK kinase kinase (MEKK2/3), suggesting that Rictor and Sin1 facilitate other cellular activities not dictated by mTORC2 [122–124].

4.1.5. mTOR in OvCa

mTOR1 is activated in 55% of epithelial OvCa and this hyper-activated mTOR is involved in cell growth, angiogenesis, and evasion of cell death [31,37,125]. Several studies have reported that nearly 41% and 26.4% of HGSC express the phosphorylated form of mTOR1 targets 4EBP1 and 70S6K, respectively, implying that mTORC1 activity is associated with a more aggressive phenotype and poor prognosis [126]. Consistently, analysis of TCGA data indicated that high expression of MTOR is associated with poor survival rates in patients with advanced stage (stage 3 + 4) HGSC (Figure 3).

5. NFκB

5.1. Structural Overview

Nuclear factor-κ light chain enhancer of activated B cells (NFκB) comprises a group of transcription factors that are divided into two classes: Class I, which include NFκB1 or p50/p105 (in which p50 is the processed product of the precursor, p105), and NFκB2 or p52/p100 (in which p52 is the processed product of p100). Class II includes RelA/p65, RelB, and c-Rel. All members have a Rel homology domain that includes the N-terminal and C-terminal domains positioned before the nuclear localization signal. In addition to the Rel homology region, members of Class II in particular, also carry a transactivation domain at the C-terminus [127,128].

5.1.1. Canonical Pathway

The NFκB canonical pathway includes NFκB1 (a complex composed of the cleaved subunit p50), IκBα, and RelA/p65. IκBα is phosphorylated by the Inhibitor Of Nuclear Factor Kappa B Kinase (IKK) complex at two N-terminal sites: ser32 and er36 [129,130]. The IKK complex is composed of IKKa, IKKβ, and IKKy (NF-kappa-B essential modulator, NEMO). Upon phosphorylation of NFκB1, the IκBα subunit undergoes ubiquitination and subsequent proteasomal degradation. This allows p50 and RelA to dimerize and translocate to the nucleus where they induce the transcription of genes
involved in inflammation, cell growth, and apoptosis. Several factors, such as substrates for antigen receptors and cytokines, can trigger activation of the canonical pathway. In addition to p50 and RelA heterodimer, p50 and c-Rel can also dimerize and enter the nucleus to initiate downstream transcription of antiapoptotic genes, such as Bcl-xL, and genes involved in checkpoint inhibition of the cell cycle [131,132].

5.1.2. Non-Canonical Pathway

In this pathway, NFκB2 is composed of p100ANK/RDH and RelB. Activation of this pathway is achieved when inflammatory cytokines, TNF and IL1, bind to their cognate receptors and subsequently signal to NFκB inducing kinase (NIK) to activate the IKK complex [133]. In this case, the IKK complex is solely composed of IKKα dimers [134]. This IKKα homodimer phosphorylates two sites on NFκB2 at serine 866 and 870, leading to the degradation of p100 into p52 [132], dimerization of p52 and RelB subunits, and their translocation to the nucleus, where they induce the transcription of genes involved in immune function specifically of B cells [132].

5.1.3. Regulation of NFκB

In addition to the regulation of the canonical NFκB pathway by the IkB/IKK complex in the cytoplasm, this pathway is regulated at multiple levels involving heterodimerization, nuclear translocation, and even after p65RelA/p50 heterodimers translocate to the nucleus. In addition, acetyltransferases in the nucleus, specifically p300/CBP, are critical in the acetylation of RelA, mainly at lysines 218, 221, 310, and 314 [135]. Lysine acetylation of RelA influence NFκB DNA binding affinity and transcriptional activation [135,136]. IKBx acts as a post-induction repressor of NF-kappaB/Rel proteins [137,138] as it contains ankyrin repeats that aid in its nuclear localization and attachment to the deacetylated form of p65/RelA, leading to the nuclear export of the NFκB [139]. Canonical NFκB activation can also be occur in an atypical manner by DNA damage and involves formation of a complex between Ataxia Telangiectasia Mutated (ATM), NEMO, and IKKs. RelA interacts through the Rel homology domain with Breast Cancer 1 (BRCA1) to enhance the transcriptional activation of NFκB target genes. This process is dependent upon the phosphorylation of p65/RelA at serine 276, and BRCA1 (Really Interesting New Gene (RING) finger domain [140]. BRCA1 was identified as a regulator of NFκB (p65/p50) activation in response to DNA-damaging agents, etoposide and camptothecin [141]. BRCA1 activates NFκB by facilitating the p65-independent recruitment of the p50 onto the promoter of responsive genes. This activation of NFκB has been shown to contribute to chemoresistance through repression of BRCA1-induced apoptosis in response to DNA damage [141].

5.1.4. PI3K-AKT-mTOR-NFκB Axis

The reciprocal interactions between the multiple nodes of PI3K-AKT-mTOR and NFκB pathways have been highlighted in myriad physiologic and pathologic contexts. In silico analysis of PI3K-AKT-mTOR and NFκB expression, and correlation in OvCa TCGA samples using KM plot (http://kmplot.com/analysis) [62] and GEPIA web tools (http://gepia.cancer-pku.cn/index.html) [2], revealed that they are not only associated with poor survival, but they also exhibited significant positive correlation at multiple nodes by both Pearson correlation, which determines the linear relationship between two continuous variables, used in combination with the Spearman correlation coefficient, which is chiefly based on ranked values for each variable (Figures 4–6).
kappaB/Rel proteins [137,138] as it contains ankyrin repeats that aid in its nuclear localization and attachment to the deacetylated form of p65/RelA, leading to the nuclear export of the NFκB [139].

Canonical NFκB activation can also occur in an atypical manner by DNA damage and involves formation of a complex between Ataxia Telangiectasia Mutated (ATM), NEMO, and IKKs. RelA interacts through the Rel homology domain with Breast Cancer 1 (BRCA1) to enhance the transcriptional activation of NFκB target genes. This process is dependent upon the phosphorylation of p65/RelA at serine 276, and BRCA1 (Really Interesting New Gene (RING) finger domain [140].

BRCA1 was identified as a regulator of NFκB (p65/p50) activation in response to DNA-damaging agents, etoposide and camptothecin [141]. BRCA1 activates NFκB by facilitating the p65-independent recruitment of the p50 onto the promoter of responsive genes. This activation of NFκB has been shown to contribute to chemoresistance through repression of BRCA1-induced apoptosis in response to DNA damage [141].

5.1.4. PI3K-AKT-mTOR-NFκB Axis

The reciprocal interactions between the multiple nodes of PI3K-AKT-mTOR and NFκB pathways have been highlighted in myriad physiologic and pathologic contexts. In silico analysis of PI3K-AKT-mTOR and NFkB expression, and correlation in OvCa TCGA samples using KM plot (http://kmplot.com/analysis) [62] and GEPIA web tools (http://gepia.cancer-pku.cn/index.html) [2], revealed that they are not only associated with poor survival, but they also exhibited significant positive correlation at multiple nodes by both Pearson correlation, which determines the linear relationship between two continuous variables, used in combination with the Spearman correlation coefficient, which is chiefly based on ranked values for each variable (Figures 4–6).

Figure 4. Correlation between RelA and the nodes of PI3K-AKT-mTOR and NFkB pathways.

Figure 5. Correlation between NFkB1 subunit and the nodes of PI3K-AKT-mTOR and NFkB pathways.
Figure 5. Correlation between NFκB1 subunit and the nodes of PI3K-AKT-mTOR and NFκB pathways.

Figure 6. Correlation between NFκB2 subunit and the nodes of PI3K-AKT-mTOR and NFκB pathways.

The PI3K catalytic subunit PI3K-p110α and its regulatory subunit p85 have been shown to directly activate NFκB [142–144]. Overexpression of the p110α subunit induced p65RelA activation and nuclear translocation. Consistently, PI3K inhibitors, LY294002, and wortmannin, as well as the dominant negative regulatory p85 subunit, inhibited NFκB activation [142]. PI3K/NFκB interaction is induced via a multi-step cascade triggered by the release of pro-inflammatory cytokines [142–144], followed by the interaction between cytokine receptors in the cytoplasm with the regulatory p85 subunit of PI3K, which in turn increases PI3K 110α catalytic activity. Consequently, activated PI3K 110α phosphorylates downstream p65RelA of NFκB followed by its nuclear translocation [142–144]. PI3K activation also phosphorylates AKT with subsequent activation of the p65RelA subunit of NFκB via phosphorylation at S534 through the IKK complex. Phospho-AKT mediates the phosphorylation of IKKα at Thr23, allowing for IKKα to phosphorylate IkB, labelling it for polyubiquitination and proteasomal degradation and phosphorylate p65RelA at S534, and hence allowing NFκB to translocate into the nucleus [145]. Furthermore, the activation of the Ras-PI3K-AKT cascade and the p38 mitogen-activated protein kinase induced NFκB activation through binding of its co-activator cAMP responsive element binding protein (CREB) [146]. Moreover, AKT can activate NFκB independent of IKK by directly phosphorylating the transactivation domain (TAD1) of the p65RelA subunit [146].

The complex crosstalk between the PI3K pathway and NFκB results in decreased survival rates in OvCa patients [147]. High expression levels of the p65 RelA subunit of NFκB, along with cleaved caspase 3, conferred poor outcomes in OvCa patients [148]. NFκB expression levels were strongly associated with chemoresistance. Mabuchi et al. [149] demonstrated that inhibition of NFκB resulted in enhanced efficacy of cisplatin in in vitro and in vivo OvCa models. Upregulation of p65 RelA subunit of NFκB increased the resistance of OvCa to carboplatin [149], and significantly enhanced the aggressiveness of OvCa cells [150]. The ability of NFκB to influence OvCa chemoresistance was attributed, in part, to its interactions with Homeobox (HOX) transcript antisense RNA (HOTAIR), a long non-coding RNA (lncRNA) that not only cooperated with NFκB to induce platinum resistance, but also decreased IkBα, allowing for constitutive activation of NFκB, suggesting a positive feedback
6. mTORC1 and NFκB Activation

mTOR downstream from AKT controls NFκB activity in PTEN-null/inactive cancer cells via interaction with and stimulation of IKK. The mTOR-associated protein Raptor is required for the ability of AKT to induce NFκB activity. This was further supported by inhibiting IKK activity in PTEN-deficient prostate cancer cells by the mTOR inhibitor rapamycin through a mechanism that may involve dissociation of Raptor from mTOR [152]. Paradoxically, IKKα has been shown to regulate mTORC1 activity in PTEN-deficient cancer cells [153,154]. In contrast, IKKβ activates mTORC1 in an AKT-dependent manner [152], and in an AKT-independent manner through the phosphorylation of the mTOR repressor TSC1 at S487 and S511 [155]. The regulation of mTORC1 by IKKβ suggests a reciprocal activation of IKKβ by mTORC1, leading to activation of a NFκB canonical pathway [152,156].

7. Therapeutic Targeting of PI3K-AKT-mTOR-NFκB in Preclinical Models of OvCa

The PI3K-AKT-mTOR-NFκB pathway is responsible not only for the aggressiveness of OvCa, but also contributes to the increased resistance to the standard chemotherapeutics, cisplatin and paclitaxel [157]. Recent decades have witnessed an unparalleled expansion of therapeutic agents designed to target the PI3K/AKT/mTOR/NFκB pathway. Several preclinical studies indicate the effectiveness of PI3K inhibitors in OvCa, either alone or in combination with other therapies. For example, isoform-specific p110β inhibitors have demonstrated a strong potency, especially against PTEN-deficient cell lines [158]. While some preclinical data suggests that OvCa cells with simultaneous mutations in KRAS and loss of PTEN depend more heavily on p110α than p110β [159], concurrent inhibition of p110α and p110β may yield optimal tumoricidal activity in OvCa [160]. Both p110α and p110β isoforms exhibit overlapping roles and the success of p110β specific inhibitors likely depends on the absence of p110α-activating mutations [161]. A combination of PARP inhibitor, Olaparib, and PI3K inhibitor, BKM120, effectively blocked the proliferation of OvCa cells with an intensified DNA damage response blockade in vitro, and synergistically inhibited the growth of PIK3CA mutant OvCa cells SKOV3, IGROV1, and HEYA8 cells. Additionally, BKM120 synergized with Olaparib to increase apoptosis as well as inhibit migration and invasion of PIK3CA mutant OvCa cells [162]. Interestingly, OvCa cells that responded favorably to the combination treatment demonstrated decreased BRCAL2 expression and decreased intraperitoneal dissemination [162]. Combining the DNA-damaging drug, doxorubicin, with a class I PI3K inhibitor, GDC-0941, in OvCa preclinical studies showed that PI3K inhibition significantly increased apoptosis, DNA damage, and the overall anti-tumorigenic effects of doxorubicin [163].

AKT protein expression was significantly increased in cisplatin-resistant A2780 OvCa cells (A2780cis) as compared to its cisplatin-sensitive counterpart [99,100]. This platinum resistance in the A2780cis cell line was overcome by AKT downregulation by siRNA [99]. The polyadenylation inhibitor cordycepin, also known as 3’-deoxyadenosine [164,165], has been shown to induce apoptosis and inhibit OvCa cell migration through inhibition of CCL5-induced AKT-NFκB signaling pathway [165]. Consistently, Aurora-A inhibitor, MK-5108, induced cell cycle arrest by inhibiting the p65 subunit of NFκB and led to the nuclear accumulation of IκBα [166]. With decreased interleukin-6 (IL-6), interleukin-8 (IL-8), macrophage chemoattractant protein-1 (MCP-1), and Growth-Regulated alpha (GRO-α). Therefore, inhibition of the NFκB pathway demonstrated anti-tumorigenic effects on OvCa stem cells.

Inhibition of the PI3K-NFκB axis also inhibited OvCa stem cells (CSCs) triggered by cisplatin. Disruption of the PI3K-NFκB loop by wortmannin reduced the OvCa CSC subpopulation [167]. A study by Gonzalez-Torres et al. [168] reported that in the SKOV3 cell line, CD44+ cells exhibited increased transcripts of stemness genes NANOG, octamer-binding transcription factor 4/3 (OCT4/3), and sex determining region Y HMG-box 2 (SOX2) with high expression levels of RelA, RelB, and
IKKα. Inhibition of the NFκB canonical pathway by dominant negative IkBα, as well as inhibition of non-canonical kinase, IKKα, by shRNAs, decreased CSC population with downregulation of stemness genes [168]. Additional studies by House et al., [169] showed that NFκB promotes OvCa tumor initiating cells in two arms: first, via the canonical pathway that supports proliferative cancer cells, and second, via the non-canonical pathway that supports ALDH+ OvCa stem cell like cells (CSCs). Another study demonstrated that CSCs produce CCL5, which activates downstream NFκB signaling and allows for the differentiation of CSCs to endothelial cells (ECs) that participate in tumor angiogenesis and further promote invasion and metastasis of OvCa cells [170].

Preclinical studies of an mTOR inhibitor revealed that CC223 disrupted the assembly of mTORC1-Raptor and mTORC2-Rictor complexes in SKOV3 cells [171]. CC223 was earlier found to inhibit the pro-survival and anti-apoptotic effects of sphingosine kinase 1 (SphK1), which is over-expressed in OvCa cells [172,173]. CC223 also blocked phosphorylation of S6K1 and AKT (Ser473), both of which are indicators of mTOR activity. Moreover, mTOR-dependent proteins, cyclin D1 and hypoxia-inducible factor-1α (HIF1α), were also decreased upon CC223 treatment together with inhibition of cell survival and proliferation and induction of apoptosis. Furthermore, restoration of mTOR activation by overexpression of a constitutively-active AKT1 (ca-AKT1) form in SKOV3 cells partially mitigated, but did not reverse, CC223-induced cytotoxicity in OvCa cells [171]. Finally, CC223-induced reactive oxygen species (ROS) production in SKOV3 cells and inhibited their in vivo growth in nude mice [171]. Another study demonstrated that a novel PI3K/mTOR dual inhibitor, CMG002, has the ability to overcome the chemo-resistance in OvCa cells to paclitaxel or cisplatin by inhibiting cell proliferation and inducing G1 cell cycle arrest and apoptosis in vitro [174]. In vivo, CMG002 suppressed the growth of OvCa in xenograft in nude mice as a monotherapy, and in combination with paclitaxel or cisplatin. CMG002 markedly inhibited the phosphorylation of mTOR (Ser2448), AKT (Ser473 and Thr308), and ribosomal protein S6 (rpS6, Ser235/236) [174].

8. Therapeutic Targeting of PI3K-AKT-mTOR-NFκB in Clinical Trials: Opportunities and Challenges

Due to its multiple downstream effectors, PI3K has become an attractive therapeutic target for OvCa. Several clinical trials that are targeting PI3K in combination with targeting its upstream activators or downstream effectors are ongoing in phase 1 and 2 clinical trials (Table 3). Targeting all Class I PI3K forms by BKM120, or Buparlisib, a dimorpholino pyrimidine derivative [175], is paired with BYL719 (alpelisib), which has targeted phosphatidylinositol 3-kinase α-selective forms [176] in a phase 1 trial. Another inhibitor of all PI3K isoforms, Copanlisib, with the greatest inhibitory activity against PI3Kα and PI3Kδ [177,178], is in a phase 1 trial with MEK162, or binimetinib, that inhibits MEK1/2. Moreover, CUDC-907, an oral small molecule inhibitor that targets both PI3K and HDAC [179] is in a phase 1 trial.

Drugs targeting AKT include AZD5363 and GSK2141795, both of which are potent pan-AKT inhibitors as well as the cell-permeable tricyclic nucleoside, Triciribine (PTX-200) and the allosteric, selective, non-ATP competitive inhibitor, Miransertib (ARQ 092) are all currently in phase 1 clinical trials. MK2206, another allosteric AKT inhibitor, is currently in phase 2.

Small molecule inhibitors that target mTOR are in phase 2 trials, including sapanisertib, as well as derivatives of macrolide compounds from rapamycin, sirolimus, everolimus, and temsirolimus. Nanoparticle albumin-bound rapamycin, along with MLN0128, an ATP-competitive kinase inhibitor, and AZD2014/vistusertib target mTOR and are in phase 1 trials.

Interestingly, several therapies have been discovered which target multiple effectors. For example, TAK228 targets PI3K/AKT/mTOR and downregulates inflammatory cytokines IL-6 [180], and is currently in a phase 2 trial. Perifosine targets PI3K/AKT/MTOR as well as NFκB [181] and is currently in phase 1 of trials (Table 3). Encapsulated formulation of curcumin together with RTKI and doxorubicin (IMX-110) is currently in a phase 1/2 trial as it has an advantage of targeting cancer cells with doxorubicin.
while inhibiting activation of signal transducer and activator of transcription 3 (STAT3) and NF-kB, as well as PI3K/AKT/mTOR [182,183] by curcumin, thus inhibiting the evolution of resistance [184,185].

While there are several drugs targeting the PI3K pathway under investigation in clinical trials, it is important to address the challenges in the clinical development of these therapies in OvCa. The success of PI3K inhibitors is inherently limited by several factors. One challenge is the toxicity of PI3K inhibitors, which is largely dependent upon isozyme specificity; pan-PI3K inhibitors have serious side effects including myelosuppression and transaminitis, while PI3Kα inhibitors result in hyperglycemia and rash [186]. Therefore, one solution to ameliorate drug toxicity would be the development of isozyme specific PI3K inhibitors with lower toxicity profiles. Another challenge includes feedback upregulation of compensatory pathways. Inhibition of PI3K blocks the phosphorylation of FOXO and thus reverses the suppression of RTKs, leading to the depression of ribosomal protein S6 kinase (S6K) and Growth Factor Receptor Bound Protein 10 (GRB10), and hence resulting in the activation of multiple RTKs and PIP3 production [186]. A similar problem is encountered with therapies that aim to induce NFκB inhibition. This inhibition causes an increased activation of the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And Pyrin Domain Containing 3 (NLRP3, NLR family pyrin domain containing 3) inflammasome, which causes a caspase-1 mediated activation of pro-inflammatory cytokines, IL-1β and IL-18 [187]. While this poses a major setback, it can be rectified by using a combination of therapies [186]. A third challenge in using PI3K inhibitors is the enhanced insulin production upon PI3K inhibition; studies have indicated that there is a dose-dependent increase in plasma levels of C-peptide and insulin with PI3K inhibitors and that this insulin secretion may activate insulin receptors and PI3K, thus reducing the overall clinical efficacy of PI3K inhibitors [176]. However, if PI3K inhibitors are used in combination with sodium-glucose co transporter-2 (SGLT2) inhibitors, or if the patient is placed on a ketogenic diet, this effect may be alleviated [186].

9. Conclusions

Among all gynecologic malignancies, HGSC is the most prevalent and lethal subtype. Women are diagnosed at advanced stages and with limited treatment options. The five-year survival for stage III/IV patients is poor and hovers around 30–40%. Recent studies have indicated that the PI3K/AKT/mTOR, as well as NFκB pathways, are highly mutated and hyper-activated in a majority of OvCa patients, and are associated with aggressive disease, therapeutic resistance, recurrence, and an overall poorer prognosis. A comprehensive investigation of the PI3K/AKT/mTOR and their interconnection with the NFκB pathway will not only expand our understanding of this ruthless disease, but also enhance the development of more effective and targeted therapies in OvCa.

Author Contributions: Conceptualization, N.S.; methodology, A.G. and N.S. data curation, A.G. and N.S.; writing—original draft preparation, A.G.; writing—review and editing, A.G. and N.S.; supervision, N.S. funding acquisition, N.S.

Funding: This work is supported by Marsha Rivkin Pilot Award, WFBMC Department of Pathology Research Pilot Funds, and R01 CA193437 (NS).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. Ca Cancer J. Clin. 2019, 69, 7–34. [CrossRef] [PubMed]
2. Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. Gepia: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017, 45, 98–102. [CrossRef] [PubMed]
3. Borley, J.; Wilhelm-Benartzi, C.; Brown, R.; Ghaem-Maghami, S. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br. J. Cancer 2012, 107, 1069–1074. [CrossRef] [PubMed]
4. Hoskins, W.J.; McGuire, W.P.; Brady, M.F.; Homesley, H.D.; Creasman, W.T.; Berman, M.; Ball, H.; Berek, J.S. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. *Am. J. Obstet. Gynecol.* 1994, 170, 974–980. [CrossRef]

5. Gasparri, M.L.; Bardhi, E.; Ruscito, I.; Papadia, A.; Farooqi, A.A.; Marchetti, C.; Bogani, G.; Ceczaccio, I.; Mueller, M.D.; Benedetti Panici, P. Pi3k/akt/mtor pathway in ovarian cancer treatment: Are we on the right track? *Geburtshilfe Frauenheilkd.* 2017, 77, 1095–1103. [CrossRef] [PubMed]

6. Mabuchi, S.; Kuroda, H.; Takahashi, R.; Sasano, T. The pi3k/akt/mtor pathway as a therapeutic target in ovarian cancer. *Gynecol. Oncol.* 2015, 137, 173–179. [CrossRef] [PubMed]

7. Martini, M.; De Santis, M.C.; Braccini, L.; Gulluni, F.; Hirsch, E. Pi3k/akt signaling pathway and cancer: An updated review. *Ann. Med.* 2014, 46, 372–383. [CrossRef] [PubMed]

8. Huang, J.; Zhang, L.; Greshock, J.; Colligon, T.A.; Wang, Y.; Ward, R.; Katsaros, D.; Lassus, H.; Butzow, R.; Godwin, A.K.; et al. Frequent genetic abnormalities of the pi3k/akt pathway in primary ovarian cancer predict patient outcome. *Genes Chromosomes Cancer* 2011, 50, 606–618. [CrossRef] [PubMed]

9. Chen, B.; Auguste, A.; Leary, A. The pi3k/akt/mtor pathway in ovarian cancer: Therapeutic opportunities and challenges. *Chin. J. Cancer* 2015, 34, 4–16. [CrossRef]

10. Philp, A.J.; Campbell, I.G.; Leet, C.; Vincan, E.; Rockman, S.P.; Whitehead, R.H.; Thomas, R.J.; Phillips, W.A. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. *Cancer Res.* 2001, 61, 7426–7429.

11. Luo, J.; Manning, B.D.; Cantley, L.C. Targeting the pi3k-akt pathway in human cancer: Rationale and promise. *Cancer Cell* 2003, 4, 257–262. [CrossRef]

12. Carpten, J.D.; Faber, A.L.; Horn, C.; Donoho, G.P.; Briggs, S.L.; Robbins, C.M.; Hostetter, G.; Boguslawski, S.; Moses, T.Y.; Savage, S.; et al. A transforming mutation in the pleckstrin homology domain of akt1 in cancer. *Nature* 2007, 448, 439–444. [CrossRef] [PubMed]

13. Nakayama, K.; Nakayama, N.; Kurman, R.J.; Cope, L.; Pohl, G.; Samuels, Y.; Velculescu, V.E.; Wang, T.L.; Shih Ie, M. Sequence mutations and amplification of pik3ca and akt2 genes in purified ovarian serous neoplasms. *Cancer Biol. Oncol.* 2006, 5, 779–785. [CrossRef] [PubMed]

14. Martins, F.C.; Santiago, I.; Trinh, A.; Xian, J.; Guo, A.; Sayal, K.; Jimenez-Linan, M.; Deen, S.; Driver, K.; Mack, M.; et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals pten loss as a common driver event and prognostic classifier. *Genome Biol.* 2014, 15, 526. [CrossRef] [PubMed]

15. Salmena, L.; Shaw, P.; Fans, I.; Rosen, B.; Risch, H.; Mitchell, C.; Sun, P.; Narod, S.A.; Kotsopoulos, J. Prognostic value of inpp4b protein immunohistochemistry in ovarian cancer. *Eur. J. Gynaecol. Oncol.* 2015, 36, 260–267.

16. De Melo, A.C.; Paulino, E.; Garces, A.H. A review of mtor pathway inhibitors in gynecologic cancer. *Oxid. Med. Cell Longev.* 2017, 2017, 480751. [CrossRef]

17. Fresno Vara, J.A.; Casado, E.; de Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. Pi3k/akt signalling pathway and cancer. *Cancer Treat. Rev.* 2004, 30, 193–204. [CrossRef] [PubMed]

18. Fruman, D.A.; Rommel, C. Pi3k and cancer: Lessons, challenges and opportunities. *Nat. Rev. Drug Discov.* 2014, 13, 140–156. [CrossRef]

19. Marshall, J.D.S.; Whitecross, D.E.; Mellor, P.; Anderson, D.H. Impact of p85alpha alterations in cancer. *Biomolecules* 2019, 9, 29. [CrossRef]

20. Posor, Y.; Eichhorn-Gruenig, M.; Puchkov, D.; Schoneberg, J.; Ullrich, A.; Lampie, A.; Muller, R.; Zarkakhsh, S.; Gulluni, F.; Hirsch, E.; et al. Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. *Nature* 2013, 499, 233–237. [CrossRef] [PubMed]

21. Das, M.; Scappini, E.; Martin, N.P.; Wong, K.A.; Dunn, S.; Chen, Y.J.; Miller, S.L.; Domin, J.; O’Bryan, J.P. Regulation of neuron survival through an intersectin-phosphoinositide 3′-kinase c2beta-akt pathway. *Mol. Cell Biol.* 2007, 27, 7906–7917. [CrossRef] [PubMed]

22. Jean, S.; Kiger, A.A. Classes of phosphoinositide 3-kinases at a glance. *J. Cell Sci.* 2014, 127, 923–928. [CrossRef] [PubMed]

23. Zhao, X.; Guan, J.L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. *Adv. Drug Deliv. Rev.* 2011, 63, 610–615. [CrossRef] [PubMed]

24. Shishido, S.; Bonig, H.; Kim, Y.M. Role of integrin alpha4 in drug resistance of leukemia. *Front. Oncol.* 2014, 4, e99. [CrossRef] [PubMed]

25. Chalhoub, N.; Baker, S.J. Pten and the pi3-kinase pathway in cancer. *Annu. Rev. Pathol.* 2009, 4, 127–150. [CrossRef] [PubMed]
26. Mohamed, A.J.; Yu, L.; Backesjo, C.M.; Vargas, L.; Faryal, R.; Aints, A.; Christensson, B.; Berglof, A.; Vihinen, M.; Nore, B.F.; et al. Bruton’s tyrosine kinase (btk): Function, regulation, and transformation with special emphasis on the ph domain. *Immunol. Rev.* 2009, 228, 58–73. [CrossRef] [PubMed]

27. Vigil, D.; Cherfils, J.; Rossman, K.L.; Der, C.J. Ras superfamily gefs and gaps: Validated and tractable targets. *Nat. Rev. Cancer* 2010, 10, 842–857. [CrossRef]

28. Bos, J.L.; Rehmann, H.; Wittinghofer, A. Gefs and gaps: Critical elements in the control of small g proteins. *Cell* 2007, 129, 865–877. [CrossRef]

29. Fruman, D.A.; Chiu, H.; Hopkins, B.D.; Bagrodia, S.; Cantley, L.C.; Abraham, R.T. The pi3k pathway in cancer. *Cell* 2017, 170, 605–635. [CrossRef]

30. Vanhaesebroeck, B.; Stephens, L.; Hawkins, P. Pi3k in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. *Nat. Rev. Mol. Cell Biol.* 2012, 13, 195–203. [CrossRef]

31. Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011, 474, 609–615. [CrossRef] [PubMed]

32. Thorpe, L.M.; Yuzugullu, H.; Zhao, J.J. Pi3k in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. *Nat. Rev. Cancer* 2015, 15, 7–24. [CrossRef] [PubMed]

33. Gray, J.W. Pik3ca is implicated as an oncogene in ovarian cancer. *Nat. Rev. Cancer* 2015, 15, 609–615. [CrossRef] [PubMed]

34. Kurman, R.J.; Shih, I.-M. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. *Am. J. Pathol.* 2016, 186, 733–747. [CrossRef] [PubMed]

35. Cai, J.; Xu, L.; Tang, H.; Yang, Q.; Yi, X.; Fang, Y.; Zhu, Y.; Wang, Z. The role of the pten pathway in human ovarian cancer cell via a gi-akt pathway. *Carcinogenesis* 2009, 30, 733–747. [CrossRef] [PubMed]

36. Spangle, J.M.; Roberts, T.M.; Zhao, J.J. The emerging role of pi3k/akt-mediated epigenetic regulation in cancer. *Biochim. Biophys. Acta Rev. Cancer* 2017, 1868, 123–131. [CrossRef]

37. Li, D.; Pan, Y.; Huang, Y.; Zhang, P.; Fang, X. Pak5 induces emt and promotes cell migration and invasion by activating the pi3k/akt pathway in ovarian cancer. *Anal. Cell Pathol.* 2018, 2018, e8073124. [CrossRef]

38. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat. Rev. Drug Discov.* 2009, 8, 630–644. [CrossRef]

39. Chou, C.H.; Wei, L.H.; Kuo, M.I.; Huang, Y.; Kao, S.; Chen, C.A.; Hsieh, C.Y. Up-regulation of interleukin-6 in human ovarian cancer cell via a gi-akt pathway. *Anal. Cell Pathol.* 2018, 2018, e8073124. [CrossRef]

40. Dituri, F.; Mazzocca, A.; Giannelli, G.; Antonaci, S. Pi3k functions in cancer progression, anticancer immunity and immune evasion by tumors. *Clin. Dev. Immunol.* 2011, 2011, 947858. [CrossRef] [PubMed]

41. Cai, H.; Xu, Y.; Huang, Y.; Zhang, P.; Fang, X. Pi3k functions in cancer progression, anticancer immunity and immune evasion by tumors. *Cancer Biol. Immunol.* 2015, 34, 186–193. [CrossRef]

42. Cheng, W.H.; Lu, P.J.; Hsiao, M.; Hsiao, C.H.; Ho, W.Y.; Cheng, P.W.; Lin, C.T.; Hong, L.Z.; Tseng, C.J. Renin activates pi3k-akt-enos signalling through the angiotensin at(1) and mas receptors to modulate central blood pressure control in the nucleus tractus solitarii. *Br. J. Pharm.* 2012, 166, 2024–2035. [CrossRef] [PubMed]

43. Yousif, N.G. Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of fak-pi3k/akt pathway. *Cell Biol. Int.* 2014, 38, 85–91. [CrossRef]
50. Le Naour, A.; Mevel, R.; Thibault, B.; Courtais, E.; Chantalat, E.; Delord, J.P.; Couderc, B.; Guillermet-Guibert, J.; Martinez, A. Effect of combined inhibition of p110 alpha pi3k isoform and stat3 pathway in ovarian cancer platinum-based resistance. *Oncotarget* **2018**, *9*, 27220–27232. [CrossRef]  
51. Kim, S.; Han, Y.; Kim, S.J.; Kim, H.S.; Kim, S.J.; Song, Y.S. Tumor evolution and chemoresistance in ovarian cancer. *NPJ Precis. Oncol.* **2018**, *2*, e20. [CrossRef] [PubMed]  
52. Carden, C.P.; Stewart, A.; Thavasu, P.; Kipps, E.; Pope, L.; Crespo, M.; Miranda, S.; Attard, G.; Garrett, M.D.; Clarke, P.A.; et al. The association of pi3 kinase signaling and chemoresistance in advanced ovarian cancer. *Mol. Cancer* **2012**, *11*, 1609–1617. [PubMed]  
53. Kinross, K.M.; Montgomery, K.G.; Kleinschmidt, M.; Waring, P.; Ivetac, I.; Tikoo, A.; Saad, M.; Hare, L.; Roh, V.; Mantamadiotis, T.; et al. An activating pik3ca mutation coupled with pten loss is sufficient to initiate ovarian tumorigenesis in mice. *J. Clin. Investig.* **2012**, *122*, 553–557. [CrossRef] [PubMed]  
54. Brasseur, K.; Gevry, N.; Asselin, E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. *Oncotarget* **2017**, *8*, 4008–4042. [CrossRef] [PubMed]  
55. Liu, Z.; Zhu, G.; Getzenberg, R.H.; Veltri, R.W. The upregulation of pi3k/akt and map kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. *J. Cell Biochem.* **2015**, *116*, 1341–1349. [CrossRef] [PubMed]  
56. Huang, C.Z.; Wang, Y.F.; Zhang, Y.; Peng, Y.M.; Liu, Y.X.; Ma, F.; Jiang, J.H.; Wang, Q.D. Cepharanthine hydrochloride reverses pglycoprotein-mediated multidrug resistance in human ovarian carcinoma a2780/taxol cells by inhibiting the pi3k/akt signaling pathway. *Oncol. Rep.* **2017**, *38*, 2558–2564. [CrossRef] [PubMed]  
57. Bumbaca, B.; Li, W. Taxane resistance in castration-resistant prostate cancer: Mechanisms and therapeutic strategies. *Acta Pharm. Sin. B* **2018**, *8*, 518–529. [CrossRef] [PubMed]  
58. Amini-Farsani, Z.; Sangtarash, M.H.; Shamsara, M.; Teimori, H. Mir-221 accelerates erbb-2-mediated mammary tumorigenesis but suppresses tumor invasion. *Cancer Res.* **2016**, *76*, 141–146. [CrossRef] [PubMed]  
59. Wu, H.; Cao, Y.; Weng, D.; Xing, H.; Song, X.; Zhou, J.; Xu, G.; Lu, Y.; Wang, S.; Ma, D. Effect of tumor suppressor gene pten on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. *Cancer Lett.* **2008**, *271*, 260–271. [CrossRef]  
60. Wu, H.; Wang, K.; Liu, W.; Hao, Q. Pten overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating krt10 expression. *Biochem. Biophys. Res. Commun.* **2014**, *444*, 141–146. [CrossRef]  
61. Peng, D.J.; Wang, J.; Zhou, J.Y.; Wu, G.S. Role of the akt/mtor survival pathway in cisplatin resistance in ovarian cancer cells. *Biochem. Biophys. Res. Commun.* **2010**, *394*, 600–605. [CrossRef] [PubMed]  
62. Györffy, B.; Lanczyk, A.; Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. *Endocr. Relat. Cancer* **2012**, *19*, 197–208. [CrossRef] [PubMed]  
63. Stratton, M.R.; Campbell, P.F.; Futreal, P.A. The cancer genome. *Nature* **2009**, *458*, 719–724. [CrossRef] [PubMed]  
64. Previs, R.A.; Sood, A.K.; Mills, G.B.; Westin, S.N. The rise of genomic profiling in ovarian cancer. *Expert Rev. Mol. Diagn.* **2016**, *16*, 1337–1351. [CrossRef] [PubMed]  
65. Gevaert, O.; Villalobos, V.; Sikic, B.I.; Plevritis, S.K. Identification of ovarian cancer driver genes by using module network integration of multi-omics data. *Interface Focus* **2013**, *3*, e20130013. [CrossRef] [PubMed]  
66. Manning, B.D.; Cantley, L.C. Akt/pkb signaling: Navigating downstream. *Cell* **2007**, *129*, 1261–1274. [CrossRef] [PubMed]  
67. Mundi, P.S.; Sachdev, J.; McCourt, C.; Kalinsky, K. Akt in cancer: New molecular insights and advances in drug development. *Br. J. Clin. Pharm.* **2016**, *82*, 943–956. [CrossRef] [PubMed]  
68. Hutchinson, J.N.; Jin, J.; Cardiff, R.D.; Woodgett, J.R.; Muller, W.J. Activation of akt-1 (pkb-alpha) can accelerate erbb-2-mediated mammary tumorigenesis but suppresses tumor invasion. *Cancer Res.* **2004**, *64*, 3171–3178. [CrossRef] [PubMed]  
69. Gonzalez, E.; McGraw, T.E. The akt kinases: Isoform specificity in metabolism and cancer. *Cell Cycle* **2009**, *8*, 2502–2508. [CrossRef]  
70. Linnerth-Petrik, N.M.; Santry, L.A.; Moorehead, R.; Jucker, M.; Wootton, S.K.; Petrik, J. Akt isoform specific effects in ovarian cancer progression. *Oncotarget* **2016**, *7*, 74820–74833. [CrossRef]
71. Fortier, A.M.; Asselin, E.; Cadrin, M. Functional specificity of akt isoforms in cancer progression. *Biomol. Concepts* 2011, 2, 1–11. [CrossRef] [PubMed]

72. Cho, H.; Thorvaldsen, J.L.; Chu, Q.; Feng, F.; Birnbaum, M.J. Akt1/pkbalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *J. Biol. Chem.* 2001, 276, 38349–38352. [CrossRef] [PubMed]

73. Cho, H.; Mu, J.; Kim, J.K.; Thorvaldsen, J.L.; Chu, Q.; Crenshaw, E.B.; 3rd; Kaestner, K.H.; Bartolomei, M.S.; Shulman, G.I.; Birnbaum, M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase akt2 (pkb beta). *Science* 2001, 292, 1728–1731. [CrossRef] [PubMed]

74. Easton, R.M.; Cho, H.; Roovers, K.; Shineman, D.W.; Mizrahi, M.; Forman, M.S.; Lee, V.M.; Szabolcs, M.; de Jong, R.; Oltersdorf, T.; et al. Role for akt3/protein kinase bgamma in attainment of normal brain size. *Mol. Cell Biol.* 2005, 25, 1869–1878. [CrossRef] [PubMed]

75. Showkat, M.; Beigh, M.A.; Andrabi, K.I. Mtor signaling in protein translation regulation: Implications in esophageal squamous cell carcinoma. *Cancers* 2017, 9(12), 1170–1177. [CrossRef] [PubMed]

76. Altomare, D.A.; Wang, H.Q.; Skele, K.L.; De Rienzo, A.; Klein-Szanto, A.J.; Godwin, A.K.; Testa, J.R. Akt and mtor phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. *Oncogene* 2004, 23, 5853–5857. [CrossRef] [PubMed]

77. Conciatori, F.; Ciu, L.; Bazzichetto, C.; Falcone, I.; Pilotto, S.; Bria, E.; Cognetti, F.; Milella, M. Mtor cross-talk in cancer and potential for combination therapy. *Cancers* 2018, 10, 23. [CrossRef] [PubMed]

78. Zois, C.E.; Harris, A.L. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. *J. Mol. Biol.* 2016, 94, 137–154. [CrossRef] [PubMed]

79. Roberts, M.S.; Woods, A.J.; Dale, T.C.; Van Der Sluijs, P.; Norman, J.C. Protein kinase b/akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. *Mol. Cell Biol.* 2004, 24, 1505–1515. [CrossRef] [PubMed]

80. Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. *Cell* 1997, 91, 231–241. [CrossRef]

81. Tzivion, G.; Dobson, M.; Ramakrishnan, G. Foxo transcription factors; regulation by akt and 14-3-3 proteins. *Biochim. Biophys. Acta* 2011, 1813, 1938–1945. [CrossRef] [PubMed]

82. Mayo, L.D.; Donner, D.B. A phosphatidylinositol 3-kinase/akt pathway promotes translocation of mdm2 from the cytoplasm to the nucleus. *Proc. Natl. Acad. Sci. USA* 2001, 98, 11598–11603. [CrossRef] [PubMed]

83. Gottlieb, T.M.; Leal, J.F.; Seger, R.; Taya, Y.; Oren, M. Cross-talk between akt, p53 and mdm2: Possible implications for the regulation of apoptosis. *Oncogene* 2002, 21, 1299–1303. [CrossRef] [PubMed]

84. Huang, J.; Manning, B.D. The tsc1-tsc2 complex: A molecular switchboard controlling cell growth. *Biochem. J.* 2008, 412, 179–190. [CrossRef] [PubMed]

85. Qin, X.; Jiang, B.; Zhang, Y. 4e-bp1, a multifactor regulated multifunctional protein. *Cell Cycle* 2016, 15, 781–786. [CrossRef] [PubMed]

86. Georgescu, M.M. Pten tumor suppressor network in pi3k-akt pathway control. *Genes Cancer* 2010, 1, 1170–1177. [CrossRef] [PubMed]

87. Blanco-Aparicio, C.; Renner, O.; Leal, J.F.; Carnero, A. Pten, more than the akt pathway. *Genes Cancer* 2008, 21, 1379–1386. [CrossRef] [PubMed]

88. Alimonti, A.; Carracedo, A.; Clohessy, J.G.; Trotman, L.C.; Nardella, C.; Egia, A.; Salmena, L.; Sampieri, K.; Haveman, W.J.; Brogi, E.; et al. Subtle variations in pten dose determine cancer susceptibility. *Nat. Genet.* 2007, 39, 454–458. [CrossRef] [PubMed]

89. Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S.H.; Zhang, J.; Signoretti, S.; Loda, M.; Roberts, T.M.; et al. Essential roles of pi(3)k-p110beta in cell growth, metabolism and tumorigenesis. *Nature* 2008, 454, 776–779. [CrossRef]

90. Terakawa, N.; Kanamori, Y.; Yoshida, S. Loss of pten expression followed by akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. *Endocr. Relat. Cancer* 2003, 10, 203–208. [CrossRef]

91. Tachibana, M.; Shibakita, M.; Ohno, S.; Kinugasa, S.; Yoshimura, H.; Ueda, S.; Fujii, T.; Rahman, M.A.; Dhar, D.K.; Nagasue, N. Expression and prognostic significance of pten product protein in patients with esophageal squamous cell carcinoma. *Cancer* 2002, 94, 1955–1960. [CrossRef] [PubMed]

92. Leupin, N.; Cenni, B.; Novak, U.; Hugli, B.; Graber, H.U.; Tobler, A.; Fey, M.F. Disparate expression of the pten gene: A novel finding in b-cell chronic lymphocytic leukaemia (b-cll). *Br. J. Haematol.* 2003, 121, 97–100. [CrossRef] [PubMed]
93. Cheong, J.W.; Eom, J.I.; Maeng, H.Y.; Lee, S.T.; Hahn, J.S.; Ko, Y.W.; Min, Y.H. Phosphatase and tensin homologue phosphorylation in the c-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br. J. Haematol. 2003, 122, 454–456. [CrossRef] [PubMed]

94. Ip, L.R.; Poulogiannis, G.; Viciano, F.C.; Sasaki, J.; Kofuji, S.; Spanswick, V.J.; Hochhauser, D.; Hartley, J.A.; Sasaki, T.; Gewinner, C.A. Loss of inpp4b causes a DNA repair defect through loss of brca1, atm and atr and can be targeted with parp inhibitor treatment. Oncotarget 2015, 6, 10548–10562. [CrossRef] [PubMed]

95. Fedele, C.G.; Ooms, L.M.; Ho, M.; Vieuxsusex, J.; O’Toole, S.A.; Millar, E.K.; Lopez-Knowles, E.; Sirratan, A.; Gurung, R.; Baglietto, L.; et al. Inositol polyphosphate 4-phosphatase ii regulates pi3k/akt signaling and is lost in human basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2010, 107, 22231–22236. [CrossRef] [PubMed]

96. Chen, Y.; Sun, Z.; Qi, M.; Wang, X.; Zhang, W.; Chen, C.; Liu, J.; Zhao, W. Inpp4b restrains cell proliferation and metastasis via regulation of the pi3k/akt/sigk pathway. J. Cell Mol. Med. 2018, 22, 2935–2943. [CrossRef]

97. Gewinner, C.; Wang, Z.C.; Richardson, A.; Teruya-Feldstein, J.; Etemadmoghadam, D.; Bowtell, D.; Barretina, J.; Lin, W.M.; Rameh, L.; Salmena, L.; et al. Evidence that inositol polyphosphate 4-phosphatase type ii is a tumor suppressor that inhibits pi3k signaling. Cancer Cell 2009, 16, 115–125. [CrossRef]

98. Hanrahan, A.J.; Schultz, N.; Westfal, M.L.; Sakr, R.A.; Giri, D.D.; Scarperi, S.; Janakiraman, M.; Olivera, N.; Stevens, E.V.; She, Q.B.; et al. Genomic complexity and akt dependence in serous ovarian cancer. Cancer Discov. 2012, 2, 56–67. [CrossRef]

99. Hahne, J.C.; Honig, A.; Meyer, S.R.; Gambaryan, S.; Walter, U.; Wischhusen, J.; Haussler, S.F.; Segerer, S.E.; Fujita, N.; Dietl, J.; et al. Downregulation of akt reverses platinum resistance of human ovarian cancers in vitro. Oncol. Rep. 2012, 28, 2023–2028. [CrossRef]

100. Hahne, J.C.; Meyer, S.R.; Gambaryan, S.; Walter, U.; Dietl, J.; Engel, J.B.; Honig, A. Immune escape of akt overexpressing ovarian cancer cells. Int. J. Oncol. 2013, 42, 1630–1635. [CrossRef]

101. Kim, S.H.; Juhnn, Y.S.; Song, Y.S. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann. N Y Acad. Sci. 2007, 1095, 82–89. [CrossRef] [PubMed]

102. Beauchamp, E.M.; Platianis, L.C. The evolution of the tor pathway and its role in cancer. Oncogene 2013, 32, 3923–3932. [CrossRef] [PubMed]

103. Yang, H.; Rudge, D.G.; Koos, J.D.; Vaidialingam, B.; Yang, H.J.; Pavletich, N.P. Mtor kinase structure, mechanism and regulation. Nature 2013, 497, 217–223. [CrossRef] [PubMed]

104. Baretic, D.; Williams, R.L. The structural basis for mtor function. Semin. Cell Dev. Biol. 2014, 36, 91–101. [CrossRef] [PubMed]

105. Yip, C.K.; Murata, K.; Walz, T.; Sabatini, D.M.; Kang, S.A. Structure of the human mtor complex i and its implications for rapamycin inhibition. Mol. Cell 2010, 38, 768–774. [CrossRef] [PubMed]

106. Bai, H.; Li, H.; Li, W.; Gui, T.; Yang, J.; Cao, D.; Shen, K. The pi3k/akt/mtor pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget 2015, 6, 25520–25532. [CrossRef]

107. Yaba, A.; Bianchi, V.; Borini, A.; Johnson, J. A putative mitotic checkpoint dependent on mtor function controls cell proliferation and survival in ovarian granulosa cells. Reprod. Sci. 2008, 15, 128–138. [CrossRef]

108. Guertin, D.A.; Sabatini, D.M. Defining the role of mtor in cancer. Cancer Cell 2007, 12, 9–22. [CrossRef]

109. Wullschleger, S.; Loewith, R.; Hall, M.N. Tor signaling in growth and metabolism. Cell 2006, 124, 471–484. [CrossRef]

110. Hong, Z.; Pedersen, N.M.; Wang, L.; Torgersen, M.L.; Stenmark, H.; Raiborg, C. Ptdins3p controls mtorc1 signaling through lysosomal positioning. J. Cell Biol. 2017, 216, 4217–4233. [CrossRef]

111. Yuan, H.X.; Russell, R.C.; Guan, K.L. Regulation of pik3c3/vps33 complexes by mtor in nutrient stress-induced autophagy. Autophagy 2013, 9, 1983–1995. [CrossRef] [PubMed]

112. Kim, Y.C.; Guan, K.L. Mtor: A pharmacologic target for autophagy regulation. J. Clin. Investig. 2015, 125, 25–32. [CrossRef] [PubMed]

113. Musa, J.; Orth, M.F.; Dallmayer, M.; Baldauf, M.; Pardo, C.; Rotblat, B.; Kirchner, T.; Leprivier, G.; Grunewald, T.G. Eukaryotic initiation factor 4e-binding protein 1 (4e-bp1): A master regulator of mrna translation involved in tumorigenesis. Oncogene 2016, 35, 4675–4688. [CrossRef] [PubMed]

114. Wang, R.; Ganesan, S.; Zheng, X.F. Yin and yang of 4e-bp1 in cancer. Cell Cycle 2016, 15, 1401–1402. [CrossRef] [PubMed]
115. Ding, M.; Van der Kwast, T.H.; Vellanki, R.N.; Foltz, W.D.; McKee, T.D.; Sonenberg, N.; Pandolfi, P.P.; Koritzinsky, M.; Wouters, B.G. The mtor targets 4e-bp1/2 restrain tumor growth and promote hypoxia tolerance in pten-driven prostate cancer. Mol. Cancer Res. 2018, 16, 682–695. [CrossRef] [PubMed]

116. Barnhart, B.C.; Lam, J.C.; Young, R.M.; Houghton, P.J.; Keith, B.; Simon, M.C. Effects of 4e-bp1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biol. 2008, 7, 1441–1449. [CrossRef]

117. Braunstein, S.; Karpisheva, K.; Pola, C.; Goldberg, J.; Hochman, T.; Yee, H.; Cangiarella, J.; Arju, R.; Formenti, S.C.; Schneider, R.J. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol. Cell 2007, 28, 501–512. [CrossRef]

118. Liu, P.; Gan, W.; Chin, Y.R.; Ogura, K.; Guo, J.; Zhang, J.; Wang, B.; Blenis, J.; Cantley, L.C.; Toker, A.; et al. Ptdins(3,4,5)p3-dependent activation of the mtorc2 kinase complex. Cancer Discov. 2015, 5, 1194–1209. [CrossRef]

119. Yang, G.; Murashige, D.S.; Humphrey, S.J.; James, D.E. A positive feedback loop between akt and mtorc2 via sin1 phosphorylation. Cell Rep. 2015, 12, 937–943. [CrossRef]

120. Huang, J.; Dibble, C.C.; Matsuzaki, M.; Manning, B.D. The tsc1-tsc2 complex is required for proper activation of mtor complex 2. Mol. Cell Biol. 2008, 28, 4104–4115. [CrossRef]

121. Thobe, K.; Sers, C.; Siebert, H. Unraveling the regulation of mtorc2 using logical modeling. Cell Commun. Signal. 2017, 15, 6. [CrossRef] [PubMed]

122. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of akt/pkb by the rictor-mtor complex. Science 2005, 307, 1098–1101. [CrossRef]

123. Oh, W.J.; Jacinto, E. Mtor complex 2 signaling and functions. Cell Cycle 2011, 10, 2305–2316. [CrossRef]

124. Cheng, J.; Zhang, D.; Kim, K.; Zhao, Y.; Zhao, Y.; Su, B. Mip1, an mekk2-interacting protein, controls mekk2 dimerization and activation. Mol. Cell Biol. 2005, 25, 5955–5964. [CrossRef] [PubMed]

125. Liu, J.; Wu, D.C.; Qu, L.H.; Liao, H.Q.; Li, M.X. The role of mtor in ovarian cancer, polycystic ovary syndrome and ovarian aging. Clin. Anat. 2018, 31, 891–898. [CrossRef]

126. Castellvi, J.; Garcia, A.; Rojo, F.; Ruiz-Marcellan, C.; Gil, A.; Baselga, J.; Ramon y Cajal, S. Phosphorylated 4e binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006, 107, 1801–1811. [CrossRef] [PubMed]

127. Gilmore, T.D. Introduction to nf-kappab: Players, pathways, perspectives. Oncogene 2006, 25, 6680–6684. [CrossRef]

128. Zheng, C.; Yin, Q.A.; Wu, H. Structural studies of nf-kappa b signaling. Cell Res. 2011, 21, 183–195. [CrossRef]

129. Hayden, M.S.; Ghosh, S. Shared principles in nf-kappab signaling. Cell 2008, 132, 344–362. [CrossRef]

130. Karin, M.; Delhase, M. The i kappa b kinase (ikk) and nf-kappa b: Key elements of proinflammatory signalling. Semin. Immunol. 2000, 12, 85–98. [CrossRef]

131. Hunter, J.E.; Leslie, J.; Perkins, N.D. C-rel and its many roles in cancer: An old story with new twists. Br. J. Cancer 2016, 114, 1–6. [CrossRef] [PubMed]

132. Sun, S.C. The noncanonical nf-kappab pathway. Immunol. Rev. 2012, 246, 125–140. [CrossRef] [PubMed]

133. Ling, L.; Cao, Z.; Goeddel, D.V. Nf-kappab-inducing kinase activates ikk-alpha by phosphorylation of ser-176. Proc. Natl. Acad. Sci. USA 1998, 95, 3792–3797. [CrossRef] [PubMed]

134. Uno, M.; Saitoh, Y.; Mochida, K.; Tsuruyama, E.; Kiyono, T.; Imoto, I.; Inazawa, J.; Yuasa, Y.; Kubota, T.; Yamaoka, S. Nf-kappab inducing kinase, a central signaling component of the non-canonical pathway of nf-kappab, contributes to ovarian cancer progression. PLoS ONE 2014, 9, e88347. [CrossRef] [PubMed]

135. Rothgiesser, K.M.; Fey, M.; Hottiger, M.O. Acetylation of p65 at lysine 314 is important for late nf-kappab-dependent gene expression. Bmc. Genom. 2010, 11, 22. [CrossRef] [PubMed]

136. Greene, W.C.; Chen, L.F. Regulation of nf-kappab action by reversible acetylation. Novartis. Found. Symp. 2004, 259, 208–222.

137. Sachdev, S.; Hoffmann, A.; Hannink, M. Nuclear localization of ikappab alpha is mediated by the second ankyrin repeat: The ikappab alpha ankyrin repeats define a novel class of cis-acting nuclear import sequences. Mol. Cell Biol. 1998, 18, 2524–2534. [CrossRef]

138. Baltimore, D. Nf-kappab is 25. Nat. Immunol. 2011, 12, 683–685. [CrossRef]

139. Chen, L.F.; Greene, W.C. Regulation of distinct biological activities of the nf-kappab transcription factor complex by acetylation. J. Mol. Med. 2003, 81, 549–557. [CrossRef]
140. Benezra, M.; Chevallier, N.; Morrison, D.J.; MacLachlan, T.K.; El-Deiry, W.S.; Licht, J.D. Brca1 augments transcription by the nf-kappab transcription factor by binding to the rel domain of the p65/rela subunit. *J. Biol. Chem.* 2003, 278, 26333–26341. [CrossRef]

141. Harte, M.T.; Gorski, J.J.; Savage, K.J.; Purcell, J.W.; Barros, E.M.; Burn, P.M.; McFarlane, C.; Mullan, P.B.; Kennedy, R.D.; Perkins, N.D.; et al. Nf-kappab is a critical mediator of brca1-induced chemoresistance. *Oncogene* 2014, 33, 713–723. [CrossRef] [PubMed]

142. Sizemore, N.; Leung, S.; Stark, G.R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the nf-kappab p65/rela subunit. *Mot. Cell Biol.* 1999, 19, 4798–4805. [CrossRef] [PubMed]

143. Reddy, S.A.; Huang, J.H.; Liao, W.S. Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in nkappab and ap-1 activation. *J. Biol. Chem.* 1997, 272, 29167–29173. [CrossRef]

144. Koul, D.; Yao, Y.; Abbruzzese, J.L.; Yung, W.K.; Reddy, S.A. Tumor suppressor mmac/pten inhibits cytokine-induced nkappab activation without interfering with the ikappab degradation pathway. *J. Biol. Chem.* 2001, 276, 11402–11408. [CrossRef] [PubMed]

145. Ozes, O.N.; Mayo, L.D.; Gustin, J.A.; Pfeffer, S.R.; Pfeffer, L.M.; Donner, D.B. Nf-kappab activation by tumour necrosis factor requires the akt serine-threonine kinase. *Nature* 1999, 401, 82–85. [CrossRef] [PubMed]

146. Madrid, L.V.; Mayo, M.W.; Reuther, J.Y.; Baldwin, A.S., Jr. Akt stimulates the transactivation potential of the rel/p65 subunit of nkappab b through utilization of the ikappa b kinase and activation of the mitogen-activated protein kinase p38. *J. Biol. Chem.* 2001, 276, 18934–18940. [CrossRef] [PubMed]

147. Annunziata, C.M.; Stavnes, H.T.; Kleinberg, L.; Berner, A.; Hernandez, L.F.; Birrer, M.J.; Steinberg, S.M.; Davidson, B.; Kohn, E.C. Nuclear factor kappab transcription factors are coexpressed and convey a poor outcome in ovarian cancer. *Cancer* 2010, 116, 3276–3284. [CrossRef] [PubMed]

148. Kleinberg, L.; Leung, S.; Risberg, B.; Stark, G.R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the nf-kappab p65/rela subunit. *Mot. Cell Biol.* 1999, 19, 4798–4805. [CrossRef] [PubMed]

149. Jinawath, N.; Vasoontara, C.; Jinawath, A.; Fang, X.; Zhao, K.; Yap, K.L.; Guo, T.; Lee, C.S.; Wang, W.; Balgley, B.M.; et al. Oncoproteomic analysis reveals co-upregulation of rela and stat5 in carboplatin resistant ovarian carcinoma. *PLoS ONE* 2010, 5, e11198. [CrossRef]

150. Hernandez, L.; Hsu, S.C.; Davidson, B.; Birrer, M.J.; Kohn, E.C.; Annunziata, C.M. Activation of nf-kappab signaling by inhibitor of nf-kappab kinase beta increases aggressiveness of ovarian cancer. *Cancer Res.* 2010, 70, 4005–4014. [CrossRef]

151. Ozes, A.R.; Miller, D.F.; Ozes, O.N.; Fang, F.; Liu, Y.; Matei, D.; Huang, T.; Nephew, K.P. Nf-kappab-hotair axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. *Oncogene* 2016, 35, 5350–5361. [CrossRef] [PubMed]

152. Dan, H.C.; Cooper, M.J.; Cogswell, P.C.; Duncan, J.A.; Ting, J.P.; Baldwin, A.S. Akt-dependent regulation of nf-([kappa]b) signaling by inhibitor of nf-kappab kinase beta increases aggressiveness of ovarian cancer. *Cancer Res.* 2010, 70, 4005–4014. [CrossRef]

153. Godwin, P.; Baird, A.M.; Heavey, S.; Barr, M.P.; O’Byrne, K.J.; Gately, K. Targeting nuclear factor-kappa b to overcome resistance to chemotherapy. *Front. Oncol.* 2013, 3, e120. [CrossRef]
158. Ni, J.; Liu, Q.; Xie, S.; Carlson, C.; Von, T.; Vogel, K.; Riddle, S.; Benes, C.; Eck, M.; Roberts, T.; et al. Functional characterization of an isoform-selective inhibitor of pi3k-p110beta as a potential anticancer agent. *Cancer Discov.* 2012, 2, 425–433. [CrossRef]

159. Schmit, F.; Utermark, T.; Zhang, S.; Wang, Q.; Von, T.; Roberts, T.M.; Zhao, J.J. Pi3k isoform dependence of pten-deficient tumors can be altered by the genetic context. *Proc. Natl Acad Sci USA* 2014, 111, 6395–6400. [CrossRef]

160. Behera, P.C.; Cho, C.F.; Chiocca, E.A.; Lawler, S.E. Bkm-120 (buparlisib): A novel pi3k phosphatidyl-inositol-3 kinase inhibitor with anti-invasive properties in glioblastoma. *Sci. Rep.* 2017, 8, 151–159. [CrossRef] [PubMed]

161. Nakamura, T.; Nakamura, M.; Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S. Targeting sphk1 as a new strategy against cancer. *Cell Death Discov.* 2017, 4, e164. [CrossRef] [PubMed]

162. Cui, Z.Y.; Park, S.J.; Jo, E.; Hwang, I.H.; Lee, K.B.; Kim, S.W.; Kim, D.J.; Joo, J.C.; Hong, S.H.; Lee, M.G.; et al. Cordycepin induces apoptosis of human ovarian cancer cells by inhibiting ccl5-mediated akt/nf-kappab signaling pathway. *Cell Death Discov.* 2018, 4, e62. [CrossRef] [PubMed]

163. Speranza, M.C.; Nowicki, M.O.; Behera, P.; Cho, C.F.; Chiocca, E.A.; Lawler, S.E. Bkm-120 (buparlisib): A phosphatidyl-inositol-3 kinase inhibitor with anti-invasive properties in glioblastoma. *Sci. Rep.* 2016, 6, e20189. [CrossRef] [PubMed]
176. Juric, D.; Rodon, J.; Tabernero, J.; Janku, F.; Burris, H.A.; Schellens, J.H.M.; Middleton, M.R.; Berlin, J.; Schuler, M.; Gil-Martin, M.; et al. Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (byl719) in pik3ca-altered solid tumors: Results from the first-in-human study. *J. Clin. Oncol.* 2018, 36, 1291–1299. [CrossRef] [PubMed]

177. Bendell, J.C.; Javle, M.; Bekaii-Saab, T.S.; Finn, R.S.; Wainberg, Z.A.; Laheru, D.A.; Weekes, C.D.; Tan, B.R.; Khan, G.N.; Zalupski, M.M.; et al. A phase 1 dose-escalation and expansion study of binimetinib (mek162), a potent and selective oral mek1/2 inhibitor. *Br. J. Cancer* 2017, 116, 575–583. [CrossRef]

178. Mensah, F.A.; Blaize, J.P.; Bryan, L.J. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: Evidence to date. *Onco. Targets* 2018, 11, 4817–4827. [CrossRef]

179. Sun, K.; Atoyan, R.; Borek, M.A.; Dellarocca, S.; Samson, M.E.; Ma, A.W.; Xu, G.X.; Patterson, T.; Tuck, D.P.; Viner, J.L.; et al. Dual hdac and pi3k inhibitor cudc-907 downregulates myc and suppresses growth of myc-dependent cancers. *Mol. Cancer* 2017, 16, 285–299. [CrossRef]

180. Caro-Vegas, C.; Bailey, A.; Bigi, R.; Damania, B.; Dittmer, D.P. Targeting mtor with mln0128 overcomes rapamycin and chemoresistant primary efusion lymphoma. *MBio* 2019, 10, e02871-18. [CrossRef]

181. Richardson, P.G.; Eng, C.; Kolesar, J.; Hideshima, T.; Anderson, K.C. Perifosine, an oral, anti-cancer agent and inhibitor of the akt pathway: Mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. *Expert Opin. Drug Metab. Toxicol.* 2012, 8, 623–633. [CrossRef]

182. Chen, W.C.; Lai, Y.A.; Lin, Y.C.; Ma, J.W.; Huang, L.F.; Yang, N.S.; Ho, C.T.; Kuo, S.C.; Way, T.D. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of tgf-beta and pi3k/akt signaling pathways in triple-negative breast cancer cells. *J. Agric. Food Chem.* 2013, 61, 11817–11824. [CrossRef] [PubMed]

183. Choi, B.H.; Kim, C.G.; Lim, Y.; Shin, S.Y.; Lee, Y.H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the pi3k/akt/nf kappa b pathway. *Cancer Lett.* 2008, 259, 111–118. [CrossRef] [PubMed]

184. Sesarman, A.; Tefas, L.; Sylvester, B.; Licarete, E.; Rauca, V.; Luptov, L.; Patras, L.; Banciu, M.; Porfire, A. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on c26 murine colon cancer cells. *Pharmacol. Rep. Pr.* 2018, 70, 331–339. [CrossRef] [PubMed]

185. Sesarman, A.; Tefas, L.; Sylvester, B.; Licarete, E.; Rauca, V.; Luptov, L.; Patras, L.; Porav, S.; Banciu, M.; Porfire, A. Co-delivery of curcumin and doxorubicin in pegylated liposomes favored the antineoplastic c26 murine colon carcinoma microenvironment. *Drug Deliv. Transl. Res.* 2019, 9, 260–272. [CrossRef] [PubMed]

186. Kaklamani, V.G.; Richardson, A.L.; Arteaga, C.L. Exploring biomarkers of phosphoinositide 3-kinase pathway activation in the treatment of hormone receptor positive, human epidermal growth receptor 2 negative advanced breast cancer. *Oncologist* 2019, 24, 305–312. [CrossRef] [PubMed]

187. Todoric, J.; Antonucci, L.; Karin, M. Targeting inflammation in cancer prevention and therapy. *Cancer Prev. Res.* 2016, 9, 895–905. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).